Gilead Sciences said recently the US Food and Drug Administration (FDA) had lifted the partial clinical hold placed on its trials testing a blood cancer drug combination.
The FDA removed the hold after a review of the safety data from each trial, the company said.
The health regulator had placed the hold on five cancer trials in January due to an imbalance in suspected and unexpected serious side effects between different arms of the studies that were reported by investigators of the trials.
The trials were evaluating the combination of magrolimab and another drug azacitidine for the treatment of two types of blood cancers called myelodysplastic syndrome and acute myeloid leukemia.
Magrolimab became part of Gilead’s pipeline through the acquisition of Forty Seven Inc for $4.9 billion in 2020.